Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

What Was Tested

The paper reports a study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.

Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH).

Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Metabolic and safety outcomes were compared between treatment arms.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Tesamorelin and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Tesamorelin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Tesamorelin could be set against what happens without it.

In the parent clinical trial, visceral fat cross-sectional area, hepatic fat fraction, and trunk-to-appendicular fat ratio were quantified using magnetic resonance imaging, proton magnetic resonance spectroscopy, and dual-energy x-ray absorptiometry, respectively, at baseline and 12 months.

What Was Measured

PubMed files the paper under topics including HIV Infections, Growth Hormone-Releasing Hormone, Magnetic Resonance Imaging, Absorptiometry, Photon, HIV Integrase Inhibitors and Drug-Related Side Effects and Adverse Reactions.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (AIDS (London, England)), a journal based in England.

More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.